China’s Clinical Research Organization Company (CRO) FMD China Raised $62 Million in a Series D Round Funding

China’s CRO company FMD China raised $62 million in a series D round funding led by Goldman Sachs and followed by Lilly Asia Ventures. The investment will be used to grow business and improve its global customer service.

Established in 2017, FMD China is an international CRO company that provides clinical development service that aligns with ICH standard. It provides domestic and overseas pharmaceutical companies and medical equipment providers with one stop clinical research services including registration, medical affairs, clinical operation, data management and biometrics, pharmacovigilance, and third party inspection.